Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
about
Eicosanoid pathway in colorectal cancer: Recent updatesLymphatic Vessels, Inflammation, and Immunity in Skin CancerCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateThe Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentA biased competition theory of cytotoxic T lymphocyte interaction with tumor nodulesMelanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapseDNA sensor cGAS-mediated immune recognitionThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsNew perspectives on type I IFNs in cancerLow-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape.Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancerMultifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsCurrent status of interleukin-10 and regulatory T-cells in cancermTOR signaling, Tregs and immune modulation.Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment.Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccinationPorous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.Classifying Cancers Based on T-cell Infiltration and PD-L1.Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer ImmunotherapyLocal Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumorAdding fuel to the fire: immunogenic intensification.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).Immunity, inflammation, and cancer: an eternal fight between good and evil.Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma.
P2860
Q26778011-297A7F11-2522-484A-B59D-FCDAC778E37CQ26778332-D091BDD2-B55E-4EC2-866E-7BAF9C278D78Q26782573-7A8EA684-B03E-419B-AE31-8FA26E4EA0BDQ26796305-50E837B5-585C-4339-8973-BF2C77BCDDAEQ27022789-BAB14FA4-5503-4ED2-BDE6-59917BF05ABBQ27311561-A8B6C654-6D79-4543-BBAB-26D7436DE22EQ27329598-8B319CCE-B20F-4930-9DF7-9B56753D9EE1Q28073115-6CAC763F-A22B-4B9C-BB39-A5975F0336E0Q28076760-3F19DD9C-85E3-4D4E-8992-40BEC08F51D7Q28084489-020A43F3-EF1A-4717-B798-E0EB0ACE0A24Q28086999-6109102C-91F8-4EA6-BA40-0A6C3193B234Q28256099-3D20E6EC-6C15-4F5B-BCFE-0521B8C4AFA3Q30363260-10E90AC4-5942-431A-ABD6-8260E4AD4D2DQ33750160-F90720DF-69C7-4B31-90DF-126D82F4D011Q33811204-D3851937-20CD-4632-8750-5E0FDC19FE4CQ33954123-982F46ED-EBC3-4659-A124-F40929AADA30Q34017104-50A8378F-4F3B-41D5-B589-2A54BB65FCB4Q34052580-42913D95-54B2-4A87-A251-FA794E598218Q34374026-25FD857D-F72B-48EE-8DB0-50899C5463ABQ34919712-787C12CA-158A-4FC6-B7D1-96EA3E8B72DEQ35163556-C08E784A-0C9A-4496-B8FA-EF81E4F18C87Q35507024-03A49B04-C2B9-456B-A9CF-FB65FBA99123Q35600299-6EAEF915-251B-4EE8-8AB0-D1135B6F24D6Q35607012-F70FA3C5-5CA0-46C1-A9F5-D8FC1B7E303FQ35634752-04D46765-042E-4E76-B592-8D88D55E3FD3Q35674821-1429BF51-8CFB-4B9B-90AE-1363F6DBAF94Q35753931-CE9A30AC-0CE9-43F0-8CE8-ECCF7CDFD30CQ35766482-3C67BA51-F0E9-4AE5-ABD0-BAB3AE8BA2B0Q35798992-9998B6D1-D695-44AA-997F-1D44375556ECQ35886393-3D0EFFBA-8483-4E28-BC3F-9C2655A8152BQ36024656-2B12F65C-4D03-4C4B-9649-CBF3445D7878Q36060283-A1C38CA2-7861-4A61-8545-76189F99E64EQ36106053-050A981C-C229-4808-806F-1D161FD07130Q36401731-65CFA87E-1856-4DE1-93C2-902D941708B9Q36710927-8485333A-2B93-4E2B-88C6-85597AAA2435Q36711042-7862A354-B6CD-488E-BE09-0A835E08CC0AQ36777149-AED5EFCE-177F-4E3E-B298-7444495EBD49Q36814030-CD37F3E6-2B73-4EF5-9A2C-88CD820CE37EQ36963494-AD1B1366-E94A-4578-9B8B-CDE0D5BB772DQ37046631-AE3CBDFB-2AF0-4F33-9521-C9D140318FA5
P2860
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cancer immunotherapy strategie ...... in the tumor microenvironment.
@en
type
label
Cancer immunotherapy strategie ...... in the tumor microenvironment.
@en
prefLabel
Cancer immunotherapy strategie ...... in the tumor microenvironment.
@en
P2093
P1476
Cancer immunotherapy strategie ...... in the tumor microenvironment.
@en
P2093
Leticia Corrales
Seng-Ryong Woo
Stefani Spranger
Thomas F Gajewski
Yuanyuan Zha
P304
P356
10.1016/J.COI.2013.02.009
P577
2013-04-08T00:00:00Z